CrossrefInfokarte
Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
Gut and Liver · 2025-05-15 · 19 (3) · 376-387
DOI: 10.5009/gnl240503 ↗Abstract
Kein Abstract verfügbar.
EUVIMED